<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871466</url>
  </required_header>
  <id_info>
    <org_study_id>8.2016</org_study_id>
    <nct_id>NCT02871466</nct_id>
  </id_info>
  <brief_title>Stem Cells Therapy in Advanced Heart Failure</brief_title>
  <official_title>Intra Cardiac Autologous Stem Cells Infusion May Improve Clinical Outcomes in Failing Heart Subjects Refractory to Maximal Drug Therapy and Internal Cardioverter With a Defibrillator (ICD) Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      stem cells therapy may be a choice therapy for advanced heart failure patients refractory to&#xD;
      medical therapy, internal cardiovertor with a defibrillator (ICD) recipients, and a previous&#xD;
      history of myocardial infarction and coronary artery revascularization. These patients,&#xD;
      without indication to receive a cardiac resynchronization therapy (CRT), may have a worsening&#xD;
      of heart failure, and symptoms of coronary artery disease. In this study we have evaluated in&#xD;
      consecutive 30 selected patients the amelioration in failing heart NYHA class,&#xD;
      hospitalization rate, echocardiographic left ventricle functionality, and associated to&#xD;
      reduction of angina after a treatment with stem cells intra thoracic infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NYHA class improvement</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reduction in hospitalization rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reduction in angor symptoms</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>stem cells infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stem cells infusion</intervention_name>
    <arm_group_label>stem cells infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  heart failure post coronary artery disease, refractory to maximal medical therapy,&#xD;
             previous coronary artery surgical revascularization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inflammatory chronic diseases, neoplastic diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raffaele Marfella, MD, PhD</last_name>
    <phone>00390815566101</phone>
    <email>raffaele.marfella@unicampania.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celestino Sardu</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Marfella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raffaele Marfella</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Marfella, MD, PhD</last_name>
      <phone>+39 0810815665110</phone>
      <email>raffaele.marfella@unicampania.it</email>
    </contact>
    <contact_backup>
      <last_name>Celestino Sardu, MD, MSc, PhD</last_name>
      <phone>+393336664543</phone>
      <email>drsarducele@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Celestino Sardu</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Marfella</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Celestino Sardu</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

